PCSK9 'Groundhog Day': Amgen’s Repatha Gains FDA Panel Backing In High-Risk Groups
This article was originally published in The Pink Sheet Daily
Executive Summary
Recommendation against broad use pending results from CV outcomes trial is a near repeat of advisory committee's deliberations a day earlier on Praluent. But Amgen drug gains one competitive advantage over Sanofi/Regeneron's PCSK9 inhibitor: a unanimous endorsement for use in homozygous familial hypercholesterolemia.
You may also be interested in...
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.